207 related articles for article (PubMed ID: 35253352)
21. The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Rudzinski ER; Anderson JR; Hawkins DS; Skapek SX; Parham DM; Teot LA
Arch Pathol Lab Med; 2015 Oct; 139(10):1281-7. PubMed ID: 25989287
[TBL] [Abstract][Full Text] [Related]
22. Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children: a report from the Children's Oncology Group.
Russell H; Swint JM; Lal L; Meza J; Walterhouse D; Hawkins DS; Okcu MF
Pediatr Blood Cancer; 2014 Jun; 61(6):970-6. PubMed ID: 24453105
[TBL] [Abstract][Full Text] [Related]
23. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.
Malempati S; Hawkins DS
Pediatr Blood Cancer; 2012 Jul; 59(1):5-10. PubMed ID: 22378628
[TBL] [Abstract][Full Text] [Related]
24. An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials.
Haduong JH; Heske CM; Allen-Rhoades W; Xue W; Teot LA; Rodeberg DA; Donaldson SS; Weiss A; Hawkins DS; Venkatramani R
Pediatr Blood Cancer; 2022 Apr; 69(4):e29511. PubMed ID: 35129294
[TBL] [Abstract][Full Text] [Related]
25. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Weiss AR; Lyden ER; Anderson JR; Hawkins DS; Spunt SL; Walterhouse DO; Wolden SL; Parham DM; Rodeberg DA; Kao SC; Womer RB
J Clin Oncol; 2013 Sep; 31(26):3226-32. PubMed ID: 23940218
[TBL] [Abstract][Full Text] [Related]
26. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
27. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Qualman S; Lynch J; Bridge J; Parham D; Teot L; Meyer W; Pappo A
Cancer; 2008 Dec; 113(11):3242-7. PubMed ID: 18985676
[TBL] [Abstract][Full Text] [Related]
29. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
[TBL] [Abstract][Full Text] [Related]
30. Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe.
Rogers TN; Seitz G; Fuchs J; Martelli H; Dasgupta R; Routh JC; Hawkins DS; Koscielniak E; Bisogno G; Rodeberg DA
Pediatr Blood Cancer; 2021 Apr; 68(4):e28938. PubMed ID: 33522706
[TBL] [Abstract][Full Text] [Related]
31. Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma.
Buszek SM; Ludmir EB; Grosshans DR; McAleer MF; McGovern SL; Harrison DJ; Okcu MF; Chintagumpala MM; Mahajan A; Paulino AC
Pediatr Blood Cancer; 2019 Nov; 66(11):e27952. PubMed ID: 31397065
[TBL] [Abstract][Full Text] [Related]
32. Aggressive Multimodality Therapy for a Urachal Rhabdomyosarcoma.
Halstead NV; Mikkilineni N; Cost CR; Cost NG
Urology; 2022 Jul; 165():e20-e24. PubMed ID: 35469802
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
[TBL] [Abstract][Full Text] [Related]
34. Genitourinary rhabdomyosarcoma: which treatment, how much, and when?
Wu HY; Snyder HM; Womer RB
J Pediatr Urol; 2009 Dec; 5(6):501-6. PubMed ID: 19640790
[TBL] [Abstract][Full Text] [Related]
35. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
[TBL] [Abstract][Full Text] [Related]
36. Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe.
Rudzinski ER; Kelsey A; Vokuhl C; Linardic CM; Shipley J; Hettmer S; Koscielniak E; Hawkins DS; Bisogno G
Pediatr Blood Cancer; 2021 Mar; 68(3):e28798. PubMed ID: 33306276
[TBL] [Abstract][Full Text] [Related]
37. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
[TBL] [Abstract][Full Text] [Related]
38. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Raney RB; Walterhouse DO; Meza JL; Andrassy RJ; Breneman JC; Crist WM; Maurer HM; Meyer WH; Parham DM; Anderson JR
J Clin Oncol; 2011 Apr; 29(10):1312-8. PubMed ID: 21357783
[TBL] [Abstract][Full Text] [Related]
39. Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group.
Minn AY; Lyden ER; Anderson JR; Million L; Arndt CA; Brown K; Hawkins DS; Donaldson SS
J Clin Oncol; 2010 Sep; 28(27):4228-32. PubMed ID: 20713850
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group.
Lawrence W; Anderson JR; Gehan EA; Maurer H
Cancer; 1997 Sep; 80(6):1165-70. PubMed ID: 9305719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
